This article is a commentary on:
Serum Total Bilirubin With Hospital Survival in Adults During Extracorporeal Membrane Oxygenation
Chunxia Wang1,2,3*†
Yucai Zhang1,2,3*†- 1Department of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 2Pediatric Extracorporeal Life Support Center, Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 3Institute of Pediatric Critical Care, Shanghai Jiao Tong University, Shanghai, China
A Commentary on
Serum total bilirubin with hospital survival in adults during extracorporeal membrane oxygenation
by Huang, R., Shao, M., Zhang, C., Fang, M., Jin, M., Han, X., and Liu, N. (2022). Front. Med. 9:914557. doi: 10.3389/fmed.2022.914557
Introduction
Extracorporeal membrane oxygenation (ECMO) is increasingly being used as a life-saving therapy for patients with cardio-pulmonary dysfunction who have failed conventional treatment (1). ECMO support removes carbon dioxide from the patient's blood and returns oxygenated blood to the patient (2, 3). However, ECMO-associated complications—e.g., activation of complement and contact systems leading to cytokine release—pose significant risks to successful patient management. Moreover, complications such as acute kidney injury, pneumonia, sepsis, and bleeding are common during ECMO support (4). Recently, ECMO-associated liver injury or direct hyperbilirubinemia (DHB) has been receiving more attention in both adult and pediatric populations due to its association with high mortality (5–9). It is noteworthy that the incidence of DHB (defined as >3 mg/dL of serum bilirubin) was as much as 73% in patients undergoing venoarterial ECMO (VA-ECMO) (7). Monitoring of serum total bilirubin (TBIL) could therefore be useful for assessing prognosis in patients receiving ECMO.
Subsections relevant for the subject
Huang et al. (9) reported on the important role of serum TBIL in predicting survival in adults on ECMO support. Their work produced several key findings: First, the patients who died within 28 days had twice the peak level of TBIL as those who survived. Multivariate logistic regression analysis indicated that a high peak TBIL was correlated with mortality risk at 28 days and total mortality after adjusting for age, ECMO mode, sepsis, lactate level, and APACHE II score (a general measure of disease severity). Second, hyperbilirubinemia after ECMO initiation was a risk factor for worse prognosis. Third, TBIL, but not aspartate transaminase (AST) or alanine aminotransferase (ALT), was an important indicator of ECMO-associated liver injury, and therefore a significant predictor of prognosis, with the cutoff value of 65 μmol/L. Fourth, peak TBIL was associated with coagulation dysfunction, and was correlated with prothrombin time (PT), activated partial thromboplastin time (APTT), prothrombin time activity (PTA), and fibrinogen (FIB) levels. Fifth, there was a potential association between the sequential organ failure assessment (SOFA) score and hyperbilirubinemia after ECMO initiation. Taken together, these results demonstrate that TBIL is an optimal biomarker for assessing hospital survival in adults during ECMO.
Discussion
An increased bilirubin concentration during the first 48 h after admission was significantly associated with adverse long-term outcome in patients with moderate to severe acute respiratory distress syndrome (ARDS) (10). Patients with severe ARDS and increased bilirubin had high mortality rates at 24, 48, and 72 h after venovenous ECMO (VV-ECMO) initiation. However, increased bilirubin values before ECMO initiation was not associated with increased in-ICU mortality (6). ECMO-associated DHB was also associated with high mortality in children receiving ECMO support (8), as reported by Huang et al. (9). Round-the-clock monitoring of serum bilirubin would therefore be beneficial for the precision management of patients receiving ECMO.
Bilirubin is formed in hepatic Kupffer cells, in the monocytic macrophages of the spleen, and in bone marrow. In a normal adult, ~250–300 mg of bilirubin is formed every 24 h, at a production rate of 3.8 mg/kg (11). DHB during VA-ECMO could be caused by the lack of pulsatile flow to end organs or by medication-induced liver injury. Moreover, circuit-induced hemolysis or a massive pathological intravascular hemolysis can contribute to the development of high mixed DHB in VA-ECMO patients. Besides DHB, ECMO-induced hemolysis leads to the most severe form of pump head thrombosis (12), and the rate of hemolysis is decreased with centrifugal pumps compared to roller pumps (13). More importantly, the causes of DHB in patients under ECMO support should be analyzed case-by-case.
Compared with non-survivors, bilirubin levels in survivors trended down on the day of ECMO initiation (14), suggesting that the timely and effective removal of bilirubin is necessary for improving outcomes. The hemolysis index (HI) assay on Abbott's Alinity CI system allows accurate determination of plasma free hemoglobin concentrations, enabling the assessment of ECMO-associated hemolysis and thereby helping to prevent and manage hemolysis-induced DHB (15, 16). Advanced strategies for the management of liver failure, including artificial liver support systems, plasma exchange, and bilirubin adsorption, are gradually seeing increased usage in critically ill patients. Huang et al. (9) showed that the SOFA score was potentially associated with hyperbilirubinemia occurrence after ECMO initiation, with a prediction accuracy of 0.800.
Currently, predicting the occurrence of ECMO-associated DHB still poses a challenge for intensivists. Integrating artificial liver support systems into the ECMO circuit might be useful for improving hospital survival of patients under ECMO support, but few data are available and these issues need further study.
Author contributions
CW and YZ drafted and edited the manuscript. Both authors contributed to the article and approved the submitted version.
Funding
This work was supported by the Science and Technology Commission of Shanghai Municipality (20Y11901300) and National Natural Science Foundation of China (82171729). CW was supported by Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant No. 20171928.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Butt W, MacLaren G. Extracorporeal membrane oxygenation 2016: an update. F1000Res. (2016) 5:750. doi: 10.12688/f1000research.8320.1
2. Bartoli CR, Koenig SC, Ionan C, Gillars KJ, Mitchell ME, Austin EH 3rd, et al. Extracorporeal membrane oxygenation versus counterpulsatile, pulsatile, and continuous left ventricular unloading for pediatric mechanical circulatory support. Pediatr Crit Care Med. (2013) 14:e424–37. doi: 10.1097/PCC.0b013e3182a551b0
3. Jenks CL, Raman L, Dalton HJ. Pediatric extracorporeal membrane oxygenation. Crit Care Clin. (2017) 33:825–41. doi: 10.1016/j.ccc.2017.06.005
4. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc. (2013) 15:172–8.
5. Kaestner F, Rapp D, Trudzinski FC, Olewczynska N, Wagenpfeil S, Langer F, et al. High serum bilirubin levels, NT-pro-BNP, and lactate predict mortality in long-term, severely ill respiratory ECMO patients. ASAIO J. (2018) 64:232–7. doi: 10.1097/MAT.0000000000000610
6. Lazzeri C, Bonizzoli M, Cianchi G, Batacchi S, Chiostri M, Fulceri GE, et al. Bilirubin in the early course of venovenous extracorporeal membrane oxygenation support for refractory ARDS. J Artif Organ. (2018) 21:61–7. doi: 10.1007/s10047-017-0979-0
7. Lyu L, Yao J, Gao G, Long C, Hei F, Ji B, et al. Incidence, risk factors, and outcomes of hyperbilirubinemia in adult cardiac patients supported by veno-arterial ECMO. Artif Organs. (2018) 42:148–54. doi: 10.1111/aor.12979
8. Alexander E, O'Sullivan D, Aganga D, Hassan S, Ibrahim SH, Absah I. Clinical implications for children developing direct hyperbilirubinemia on extracorporeal membrane oxygenation. J Pediatr Gastroenterol Nutr. (2022) 74:333–7. doi: 10.1097/MPG.0000000000003364
9. Huang R, Shao M, Zhang C, Fang M, Jin M, Han X, et al. Serum total bilirubin with hospital survival in adults during extracorporeal membrane oxygenation. Front Med. (2022) 9:914557. doi: 10.3389/fmed.2022.914557
10. Dizier S, Forel JM, Ayzac L, Richard JC, Hraiech S, Lehingue S, et al. Early hepatic dysfunction is associated with a worse outcome in patients presenting with acute respiratory distress syndrome: a post-hoc analysis of the ACURASYS and PROSEVA studies. PLoS ONE. (2015) 10:e0144278. doi: 10.1371/journal.pone.0144278
11. Berk PD, Howe RB, Bloomer JR, Berlin NI. Studies of bilirubin kinetics in normal adults. J Clin Invest. (1969) 48:2176–90. doi: 10.1172/JCI106184
12. Appelt H, Philipp A, Mueller T, Foltan M, Lubnow M, Lunz D, et al. Factors associated with hemolysis during extracorporeal membrane oxygenation (ECMO)-Comparison of VA-versus VV ECMO. PLoS ONE. (2020) 15:e0227793. doi: 10.1371/journal.pone.0227793
13. Johnson KN, Carr B, Mychaliska GB, Hirschl RB, Gadepalli SK. Switching to centrifugal pumps may decrease hemolysis rates among pediatric ECMO patients. Perfusion. (2022) 37:123–7. doi: 10.1177/0267659120982572
14. Freundt M, Lunz D, Philipp A, Panholzer B, Lubnow M, Friedrich C, et al. Impact of dynamic changes of elevated bilirubin on survival in patients on veno-arterial extracorporeal life support for acute circulatory failure. PLoS ONE. (2017) 12:e0184995. doi: 10.1371/journal.pone.0184995
15. Bürki C, Volleberg M, Brunner D, Schmugge M, Hersberger M. Using the hemolysis index of Abbott's Alinity c for the measurement of plasma free hemoglobin in ECMO patients. Clin Biochem. (2022) 100:67–70. doi: 10.1016/j.clinbiochem.2021.11.010
Keywords: bilirubin, hospital survival, ECMO, venoarterial, venovenous, timing
Citation: Wang C and Zhang Y (2022) Commentary: Serum total bilirubin with hospital survival in adults during extracorporeal membrane oxygenation. Front. Med. 9:1022207. doi: 10.3389/fmed.2022.1022207
Received: 18 August 2022; Accepted: 29 August 2022;
Published: 28 September 2022.
Edited by:
Luo Zhe, Fudan University, ChinaReviewed by:
Kanhua Yin, Washington University in St. Louis, United StatesCopyright © 2022 Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chunxia Wang, karencx0465@163.com; Yucai Zhang, zyucai2018@163.com
†ORCID: Chunxia Wang orcid.org/0000-0003-4550-5208
Yucai Zhang orcid.org/0000-0002-4905-3600